Cite
HARVARD Citation
Alsoud, D. et al. (n.d.). P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn's disease: a Belgian multi-centric cohort study. Journal of Crohn's and colitis. pp. i516-i517. [Online].